Review
Biochemistry & Molecular Biology
Karim E. Shalaby, Omar M. A. El-Agnaf
Summary: Gene therapy has the potential to replace current treatments for Parkinson's disease and has been shown to be safe and effective in current trials.
Review
Biochemistry & Molecular Biology
Sri Jayanti, Rita Moretti, Claudio Tiribelli, Silvia Gazzin
Summary: With the increase in life expectancy, the prevalence of Parkinson's disease is expected to rise, but the diagnosis still relies on clinical symptoms. Current treatments mainly focus on alleviating symptoms without stopping or slowing down disease progression. Therefore, exploring the therapeutic potential of bilirubin in PD is crucial for the development of disease-modifying treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Health Care Sciences & Services
Tove Henriksen, Harry Staines
Summary: The study evaluated reasons for discontinuation of subcutaneous apomorphine infusion (SCAI) in Parkinson's disease patients, finding that main factors included adverse events, death, and treatment dissatisfaction. For the first 6 years of treatment, somnolence and hallucinations were the predominant side effects leading to discontinuation.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Chemistry, Multidisciplinary
Junguang Wu, Xuejing Cui, Pu Chun Ke, Monika Mortimer, Xiaoyu Wang, Lin Bao, Chunying Chen
Summary: Parkinson's disease is a complex multi-factorial disease with no cure, only mitigative therapies available at present. The development of nanomedicine has provided new opportunities for finding neuroprotective and neurorestorative therapies for PD. By exploring various mechanisms underlying PD pathology and discussing nanomaterial-based treatment strategies, there is potential for targeted therapies to be developed in the future.
Review
Biochemistry & Molecular Biology
Keelan Jagaran, Moganavelli Singh
Summary: Neurodegenerative disorders result in the gradual degeneration of axons and neurons in the central nervous system, causing major disruptions in patients' lives. Current treatments are only palliative, highlighting the need for a therapeutic strategy targeting the root cause of the diseases. The synergistic use of gene therapy and nanomedicine shows promise in effectively treating these diseases by targeting the causative mutated genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Jannik Prasuhn, Ryan L. Davis, Kishore R. Kumar
Summary: Parkinson's disease is complicated and mitochondrial dysfunction plays a key role in its pathophysiology. While there are still gaps in knowledge, targeting various aspects of mitochondrial function and using combined therapeutic approaches may offer the best chance for developing effective novel therapies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Zhan-Miao Yi, Sarah Willis, Yuan Zhang, Na Liu, Qi-Yu Tang, Suo-Di Zhai
Summary: This study aimed to examine the impact of a collaborative pharmaceutical care service (CPCS) on medication safety and patient-reported outcomes for Parkinson's disease (PD) patients. Comparisons were made between PD outpatients receiving the CPCS and those receiving standard of care, showing differences in medication management. The CPCS was found to effectively resolve drug-related problems and improve medication regimens, medication adherence, and quality of life through patient education and dosage adjustments.
FRONTIERS IN PHARMACOLOGY
(2022)
Letter
Medicine, General & Internal
Kurt Stoschitzky
Summary: In the SECURE trial, it was found that the use of a polypill containing aspirin, ramipril, and atorvastatin significantly reduced the risk of cardiovascular events in older patients with recent myocardial infarction. However, the absence of beta-blockers in this polypill raised questions as these drugs have been known to be effective after myocardial infarction and are recommended in current guidelines.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Geriatrics & Gerontology
Michelle H. S. Tosin, Christopher G. Goetz, Dharah P. C. F. Bispo, Henrique B. Ferraz, Marco Antonio A. Leite, Deborah A. Hall, Glenn T. Stebbins, Beatriz Guitton R. B. Oliveira
Summary: This study aims to present the development process and clinimetric testing plan of the Parkinson's Disease Medication Adherence Scale (PD-MAS). Through consecutive steps, the research team successfully developed a scale that can measure the multidimensional and multifactorial components of medication adherence in patients with Parkinson's disease. This is important for improving the management of Parkinson's disease.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Review
Cell Biology
Hamed Mirzaei, Saman Sedighi, Ebrahim Kouchaki, Erfaneh Barati, Ehsan Dadgostar, Michael Aschner, Omid Reza Tamtaji
Summary: Research has shown that probiotics can improve symptoms in patients with Parkinson's disease, and mediate pharmacological effects by targeting cellular and molecular processes.
CELLULAR AND MOLECULAR NEUROBIOLOGY
(2022)
Article
Cell Biology
Jun Xue, Yifan Wu, Yuting Bao, Minglai Zhao, Fangzhou Li, Jing Sun, Yimin Sun, Jian Wang, Liang Chen, Ying Mao, Jeffrey S. Schweitzer, Bin Song
Summary: Cell replacement therapy has potential in treating Parkinson's disease (PD), but it faces significant barriers before becoming a clinically practical option. These barriers include safe and standardized surgical procedures, appropriate perioperative medication regimens, long-term graft survival and incorporation, and standardized follow-up measures. This review provides an overview of the current status of cell therapy for PD, with a focus on these critical requirements, to guide its implementation in Parkinson's clinics.
AGEING RESEARCH REVIEWS
(2023)
Review
Immunology
Manlian Zhu, Xia Liu, Yiru Ye, Xiumei Yan, Yiwen Cheng, Longyou Zhao, Feng Chen, Zongxin Ling
Summary: Parkinson's disease is a common neurodegenerative disease characterized by motor dysfunction. Gut dysbiosis is involved in the development and progression of PD, and the gut microbiota can be considered as a potential diagnostic and therapeutic target. Gut dysbiosis influences the progression and onset of PD by increasing intestinal permeability, aggravating neuroinflammation, aggregating abnormal levels of alpha-synuclein fibrils, increasing oxidative stress, and decreasing neurotransmitter production.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Jeffrey Clement, Maura Jacobi, Brad N. Greenwood
Summary: The disruption caused by Covid-19 has impacted patients' access to and adherence to chronic medications, leading to an increase in discontinuation rates for certain drugs. Despite most US patients being able to access medications during the early months of the pandemic, they were still more likely to discontinue their therapies compared to pre-Covid months. Additionally, there was a noticeable decline in new patients accessing certain vital therapies.
Article
Multidisciplinary Sciences
Yadi Liu, Elizabeth P. Lyden, Renae Furl, Joshua Havens
Summary: In this study, participants preferred local pharmacies over mail-order pharmacies for ART prescription services and considered ease of refilling to be the most important pharmacy attribute. Two-thirds of the participants believed that mail-order pharmacy mandates negatively affected their health.
Editorial Material
Behavioral Sciences
Olivier Uwishema, Helen Onyeaka, Rawa Badri, Ayse Nazli Yucel, Ahmet Kayhan Korkusuz, Abayomi Oyeyemi Ajagbe, Amro Abuleil, Celine Chaaya, Baraa H. M. Alhendawi, Elie Chalhoub
Summary: Parkinson's disease is a progressive neurodegenerative disease characterized by a decrease in dopaminergic neurons. Its symptoms include motor and non-motor dysfunctions, and there is currently no cure for the disease. Researchers are exploring new therapies such as the replacement of neurons, alpha-synuclein, and apomorphine.
BRAIN AND BEHAVIOR
(2022)
Review
Clinical Neurology
P. D. Delgado-Lopez, S. Ortega-Cubero, J. J. Gonzalez Bernal, E. Cubo-Delgado
Summary: There is currently no formal indication for seizure prophylaxis in neurosurgical oncology patients. This study aimed to explore the effectiveness of antiepileptic prophylaxis in patients with meningioma and no history of seizures through a systematic review and meta-analysis.
Review
Clinical Neurology
R. Lopez-Blanco, A. Sorrentino Rodriguez, E. Cubo, I. Gabilondo, D. Ezpeleta, M. A. Labrador-Espinosa, A. Sanchez-Ferro, C. Tejero, M. Matarazzo
Summary: This study evaluated the impact of new technologies on Spanish neurology and found that advanced neuroimaging, biosensors, electrophysiology and neurostimulation, and telemedicine are widely used in the field. Madrid has the highest number of communications related to new technologies.
Article
Neurosciences
Diego Santos Garcia, Teresa de Deus Fonticoba, Carlos Cores, Ester Suarez Castro, Jorge Hernandez Vara, Silvia Jesus, Pablo Mir, Marina Cosgaya, Maria Jose Marti, Pau Pastor, Iria Cabo, Manuel Seijo, Ines Legarda, Barbara Vives, Nuria Caballol, Javier Ruiz Martinez, Ioana Croitoru, Esther Cubo, Javier Miranda, Maria Gema Alonso Losada, Carmen Labandeira, Nuria Lopez Ariztegui, Mabel Morales-Casado, Isabel Gonzalez Aramburu, Jon Infante, Sonia Escalante, Noemi Bernardo, Marta Blazquez Estrada, Manuel Menendez Gonzalez, Juan Garcia Caldentey, Carmen Borrue, Lydia Vela, Maria Jose Catalan, Victor Gomez Mayordomo, Monica Kurtis, Cristina Prieto, Carlos Ordas, Victor Nogueira, Lydia Lopez Manzanares, Maria Asuncion Avila Rivera, Victor Puente, Jose Manuel Garcia Moreno, Berta Solano Vila, Maria Alvarez Sauco, Francisco Carrillo Padilla, Juan Carlos Martinez Castrillo, Pilar Sanchez Alonso, Itziar Gaston, Jaime Kulisevsky, Caridad Valero, Oriol de Fabregues, Jessica Gonzalez Ardura, Luis Manuel Lopez Diaz, Pablo Martinez-Martin
Summary: This study analyzed the frequency, causes, and predictors of acute hospitalization in a cohort of Parkinson's disease patients in Spain. The results showed that falls were the most common cause of hospitalization and an independent predictor of acute hospitalization in Parkinson's disease patients.
JOURNAL OF PARKINSONS DISEASE
(2023)
Article
Clinical Neurology
Diego Santos-Garcia, Teresa de Deus Fonticoba, Carlos Cores Bartolome, Maria J. Feal Painceiras, Jose M. Paz Gonzalez, Cristina Martinez Miro, Silvia Jesus, Miquel Aguilar, Pau Pastor, Lluis Planellas, Marina Cosgaya, Juan Garcia Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernandez Vara, Iria Cabo, Lydia Lopez Manzanares, Isabel Gonzalez Aramburu, Maria A. Avila Rivera, Victor Gomez Mayordomo, Victor Nogueira, Victor Puente, Julio Dotor Garcia-Soto, Carmen Borrue, Berta Solano Vila, Maria Alvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martinez Castrillo, Pilar Sanchez Alonso, Maria G. Alonso Losada, Nuria Lopez Ariztegui, Itziar Gaston, Jaime Kulisevsky, Marta Blazquez Estrada, Manuel Seijo, Javier Ruiz Martinez, Caridad Valero, Monica Kurtis, Oriol de Fabregues, Jessica Gonzalez Ardura, Ruben Alonso Redondo, Carlos Ordas, Luis M. L. Lopez Diaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir
Summary: Visual hallucinations and subjective cognitive complaints in Parkinson's disease are associated with cognitive impairment. This study aimed to determine the association between visual hallucinations and cognitive complaints and the risk of developing cognitive impairment in Parkinson's disease patients with normal cognition. The results showed that visual hallucinations were associated with the development of cognitive impairment, and the presence of both visual hallucinations and cognitive complaints increased the probability of developing cognitive impairment.
JOURNAL OF CLINICAL NEUROLOGY
(2023)
Article
Clinical Neurology
Stuart H. Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi
Summary: This study evaluated the timing of motor improvement in Parkinson's disease patients with OFF episodes using carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO). Results showed that mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3 at 15 and 30 minutes following the first daily CD/LD dose, and FULL ON was achieved by 6.5% and 41.8% of patients, respectively. With an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7% and 81.0% of patients, respectively. In conclusion, concomitant administration of SL-APO with CD/LD may be beneficial for delayed ON.
NEURODEGENERATIVE DISEASE MANAGEMENT
(2023)
Article
Clinical Neurology
Aron Emmi, Michele Sandre, Francesco Paolo Russo, Giulia Tombesi, Federica Garri, Marta Campagnolo, Miryam Carecchio, Roberta Biundo, Gaya Spolverato, Veronica Macchi, Edoardo Savarino, Fabio Farinati, Piero Parchi, Andrea Porzionato, Luigi Bubacco, Raffaele De Caro, Gabor G. Kovacs, Angelo Antonini
Summary: This study revealed the presence of neuronal dysfunction and reactive gliosis in the duodenum of patients with Parkinson's disease, suggesting that the enteric nervous system is involved in the pathophysiology of the disease.
MOVEMENT DISORDERS
(2023)
Article
Neurosciences
Vanessa Porrini, Andrea Pilotto, Marika Vezzoli, Annamaria Lanzillotta, Michele M. Gennari, Sonia Bonacina, Antonella Alberici, Rosanna Turrone, Arianna Bellucci, Angelo Antonini, Alessandro Padovani, Marina Pizzi
Summary: Although the key neuropathological hallmarks of Parkinson's disease (PD) are known, the underlying pathogenic mechanisms of the disease still need to be elucidated. This study focused on evaluating the levels and activity of c-Rel protein, which may be involved in PD pathophysiology. The findings suggest that PD is characterized by the loss of NF-κB/c-Rel activity, and the reduction of c-Rel DNA-binding could potentially serve as a novel biomarker for PD.
NEUROBIOLOGY OF DISEASE
(2023)
Correction
Clinical Neurology
Federica Garri, Dario Ciprietti, Lisa Lerjefors, Andrea Landi, Manuela Pilleri, Roberta Biundo, Leonardo Salviati, Miryam Carecchio, Angelo Antonini
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Fabrizio Stocchi, Paolo Barone, Giuseppe Bellelli, Andrea Fagiolini, Luigi Ferini Strambi, Sandro Sorbi, Alessandro Padovani
Summary: The diagnosis of depression in Parkinson's disease is challenging due to overlapping symptoms. A panel of Italian specialists reached a consensus that depression is a risk factor for Parkinson's disease, with neuropathological abnormalities playing a role. Multimodal and SSRI antidepressants are confirmed as effective options for treating depression in Parkinson's disease.
NEUROLOGICAL SCIENCES
(2023)
Letter
Clinical Neurology
Federica Garri, Dario Ciprietti, Lisa Lerjefors, Andrea Landi, Manuela Pilleri, Roberta Biundo, Leonardo Salviati, Miryam Carecchio, Angelo Antonini
NEUROLOGICAL SCIENCES
(2023)
Article
Neurosciences
Diego Santos-Garcia, Teresa de Deus Fonticoba, Carlos Cores Bartolome, Maria J. Feal Painceiras, Maria Cristina Iniguez-Alvarado, Iago Garcia Diaz, Silvia Jesus, Maria Teresa Buongiorno, Lluis Planellas, Marina Cosgaya, Juan Garcia Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernandez Vara, Iria Cabo, Lydia Lopez Manzanares, Isabel Gonzalez Aramburu, Maria A. Avila Rivera, Victor Gomez Mayordomo, Victor Nogueira, Victor Puente, Julio Dotor Garcia-Sotos, Carmen Borrue, Berta Solano Vila, Maria Alvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martinez Castrillo, Pilar Sanchez Alonso, Maria G. Alonso Losada, Nuria Lopez Ariztegui, Itziar Gaston, Jaime Kulisevsky, Manuel Menendez Gonzalez, Manuel Seijo, Javier Ruiz Martinez, Caridad Valero, Monica Kurtis, Jessica Gonzalez Ardura, Ruben Alonso Redondo, Carlos Ordas, Luis M. Lopez Diaz, Darrian McAfee, Matilde Calopa, Fatima Carrillo, Francisco Escamilla Sevilla, Eric Freire-Alvarez, Juan Carlos Gomez Esteban, Rocio Garcia Ramos, Maria Rosario Isabel Luquin, Irene Martinez-Torres, Angel Sesar Ignacio, Pablo Martinez-Martin, Pablo Mir
Summary: This study applied the MNCD classification to Parkinson's disease patients and analyzed its correlation with quality of life and disease severity. The results showed that a more advanced MNCD stage was associated with poorer quality of life and greater disease severity. Therefore, MNCD could be a useful tool for monitoring disease progression in Parkinson's disease.
JOURNAL OF PARKINSONS DISEASE
(2023)
Review
Neurosciences
Valentina D'Onofrio, Nicoletta Manzo, Andrea Guerra, Andrea Landi, Valentina Baro, Sara Maeaettae, Luca Weis, Camillo Porcaro, Maurizio Corbetta, Angelo Antonini, Florinda Ferreri
Summary: Deep brain stimulation (DBS) is a promising treatment for neurological disorders, but its mechanisms of action are not fully understood. Transcranial magnetic stimulation (TMS) combined with DBS provides a unique approach to investigate the neurophysiology of the brain. Experimental studies have shown that DBS modulates cortical excitability and plasticity, which may contribute to its therapeutic effects. However, safety concerns limit the application of the TMS-DBS approach.
Article
Neurosciences
Aron Emmi, Stefania Rizzo, Luisa Barzon, Michele Sandre, Elisa Carturan, Alessandro Sinigaglia, Silvia Riccetti, Mila Della Barbera, Rafael Boscolo-Berto, Patrizia Cocco, Veronica Macchi, Angelo Antonini, Monica De Gaspari, Cristina Basso, Raffaele De Caro, Andrea Porzionato
Summary: Neurological manifestations are common in COVID-19 patients, and this study found evidence of SARS-CoV-2 infection in the central nervous system. The researchers observed viral RNA and SARS-CoV-2-immunoreactive neurons in specific regions of the brain in COVID-19 patients. In addition, inflammation was observed in affected brainstem regions, indicating a role of brainstem inflammation in COVID-19. Further investigations are needed to understand the potential implications for neurodegenerative diseases like Parkinson's.
NPJ PARKINSONS DISEASE
(2023)
Article
Clinical Neurology
Angelo Antonini, Aron Emmi, Marta Campagnolo
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Summary: This article reports the results of a 52-week open-label registrational trial that evaluated the safety, tolerability, and efficacy of 24-hour foslevodopa/foscarbidopa continuous subcutaneous infusion in patients with advanced Parkinson's disease. The findings suggest that this treatment has the potential to improve motor control, sleep quality, and quality of life in patients with Parkinson's disease.
NEUROLOGY AND THERAPY
(2023)
